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killed by Intraglobin to a similar degree compared to 
Pentaglobin. Opsonic IgG antibodies against E. faecalis 
were directed against LTA, while opsonic antibodies in 
Pentaglobin were primarily directed against other cell wall 
carbohydrates. In a mouse bacteremia model, Pentaglobin 
was more protective than Intratect against Staphylococcus 
aureus, while Intratect reduced colony counts better than 
normal rabbit serum or saline.
Conclusions All tested human immunoglobulin prepa-
rations contain opsonic and protective antibodies against 
targets present on multiresistant Gram-positive and Gram-
negative bacteria. Enrichment of these preparations with 
IgM increases the protective efficacy against some strains, 
probably due to antibodies directed against cell wall 
carbohydrates.
Keywords Immune globuline preparations · IgG · IgM · 
Nosocomial pathogens · Opsonic killing ·  Protective 
efficacy · Animal model
Introduction
Multiresistant nosocomial pathogens often cause life-threat-
ening infections that are sometimes untreatable with cur-
rently available antibiotics and are therefore one of the most 
serious problems in modern medicine. A recent report from 
the Centers for Disease Control and Prevention (CDC) esti-
mates that in the US about two million people acquire infec-
tions with resistant bacteria, and that probably about 23,000 
patients die each year as a direct consequence of these infec-
tions [1]. Gram-positive bacteria account for a large propor-
tion, and staphylococci and enterococci are the most impor-
tant bacterial species causing these mostly hospital-acquired 
infections that often lead to extended hospital stay and excess 
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Purpose We compared different immunoglobulin prepa-
rations containing IgG (Intraglobin/Intratect) or a mixture 
of IgG, IgA, and IgM (Pentaglobin) to assess the opsonic 
and protective efficacy of human immunoglobulin prepara-
tions against multiresistent nosocomial pathogens.
Materials and methods Clinical isolates of E. coli, Kleb-
siella pneumoniae, Pseudomonas aeruginosa, Entero-
coccus faecalis, Enterococcus faecium, and Staphylococ-
cus aureus were tested by opsonophagocytic assay using 
immunologobulin preparations at dilutions usually obtained 
in patients. The target antigens of opsonic antibodies were 
characterized by opsonophagocytic inhibition assays, and 
the protective efficacy in vivo was tested in a mouse bacte-
remia model as previously described.
Results All strains were killed to at least 50 % by 
Pentaglobin. One P. aeruginosa strain was not efficiently 
killed by Intraglobin (23 %) but the other strains were 
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mortality. Multiresistant Staphylococcus aureus cause pneu-
monia, skin, wound, bloodstream and surgical site infec-
tions. About 80,000 S. aureus infections have been reported 
in the US per year with about 12,000 deaths caused by bac-
teria resistant to methicillin (MRSA) [1]. High rates are also 
seen for enterococci, mainly Enterococcus faecium resistant 
to vancomycin (VRE) causing bloodstream infections, uri-
nary tract infections, and foreign-body infections (e.g., cath-
eters, stents, CNS shunts, artificial heart valves, etc.) mostly 
in immunocompromised patients [2–4]. For the US, it is esti-
mated that about 66,000 enterococcal infections occur each 
year, and about 20,000 of these are due to multiple-drug 
resistant (i.e., VRE) with about 1,300 deaths per year [1]. 
Multiresistance in Gram-negative bacteria is mostly due to 
extended-spectrum betalactamases (ESBL) or carbapene-
mases. ESBL-producing Enterobacteriaceae are increasingly 
isolated in patients and even otherwise healthy individuals 
[5]. These bacteria can cause bloodstream infections and are 
responsible for approximately 26,000 cases and 1,700 deaths 
per year [1]. Especially worrisome is a novel threat associ-
ated with resistance determinants against carbapenems, cur-
rently the antibiotics with the broadest spectrum. In the US, 
more than 9,000 healthcare-associated infections are caused 
by carbapenem-resistant Enterobacteriaceae (K. pneumoniae 
and E. coli) and 600 deaths result from these infections each 
year [1]. Similar trends and incidences have been reported in 
Europe (http://www.ecdc.europa.eu/en/activities/surveillance/
EARS-Net/Pages/index.aspx).
Immunotherapy, either through active immunization, or 
by passive immunotherapy, is among the most promising 
alternative approaches to fight these strains [4, 6]. While 
the development of novel vaccines against multiresistant 
nosocomial pathogens is pursued by many of the leading 
pharmaceutical companies, no preparation has yet been 
introduced into the market [7]. Passive immunotherapy, 
either through monoclonal antibodies, or through hyperim-
munoglobulins, may be an attractive addition to the cur-
rently available treatment options. However, no good data 
exist to support the usage of these preparations to prevent 
and/or treat infections in hospitalized patients.
Intravenous application of immunoglobulins from 
healthy volunteers has been used for a number of indica-
tions, e.g., immunoglobulin substitution (i.v.) in patients 
with agammaglobulinemia, and as a supportive therapy for 
bacterial infections, Kawasaki disease, or Guillain-Barré 
syndrome. Most currently available antibody preparations 
contain only IgG and several studies could not demonstrate 
a benefit of these antibodies in the prevention and treat-
ment of bacterial infections. However, in the initial immune 
response against bacterial pathogens, IgM plays an impor-
tant role and the production of a compound containing not 
only IgG but also IgA and IgM may therefore offer the 
advantage of an “innate” immune protection against bacteria 
[8]. Here, we investigate and compare the efficacy of pro-
tection of different antibody preparations with and without 
IgM and demonstrate that IgM provides a better protection 
in vivo and in vitro against some nosocomial pathogens.
Materials and methods
Bacterial strains, antibody preparations, and antigens
Bacterial strains, antibodies, and antigens used in this study 
are listed in Table 1. Immunoglobulin preparations were 
obtained from Biotest, and antigens were either produced 
in our lab according to previously described methods (i.e., 
LTA [9] or purchased from Sigma (St. Louis, MO).
Opsonophagocytic assay
Opsonophagocytic killing was assessed as described 
by Theilacker et al. [10] using 1.7 % baby rabbit serum 
(Cedarlane) as complement source, and rabbit serum 
raised against purified lipoteichoic acid (anti-LTA) from 
E. faecalis 12030 as positive control [11–13]. Bacte-
ria were incubated and grown to mid-exponential phase 
(OD650nm = 0.400). Equal volumes of bacterial suspen-
sion (2.5 × 107 per mL), leukocytes (2.5 × 107 per mL), 
complement source (1.7 % final concentration), and 
either anti-LTA rabbit serum, immunoglobulin prepara-
tions or heat-inactivated immune rabbit serum (as control) 
were combined and incubated on a rotor rack at 37 °C for 
90 min. After incubation, colony-forming units (CFUs) sur-
viving in the tubes with bacteria were quantified by agar 
culture of serial dilutions. Percentage of killing was calcu-
lated by comparing the colony counts at 90 min (t90) of a 
control without PMNs (PMNneg) to the colony counts of a 
tube that contained all four components using the follow-
ing formula: {[(mean CFU PMNneg at t90) − (mean CFU at 
t90)]/(mean CFU PMNneg at t90)} × 100.
Proteinase K and sodium meta-periodate treatment 
for inhibition experiments
Bacterial strain E. faecalis 12030 was cultured overnight in 
TSB, harvested by centrifugation (8,000 rpm, 10 min, 4 °C), 
and washed three times with PBS. Treatment of bacterial 
cells with proteinase K was performed as described previ-
ously [14]. In brief, bacterial cells (≈109 cfu/mL) were incu-
bated with proteinase K (Sigma) at a final concentration of 
0.1 mg/mL and 5 mM calcium chloride at 54 °C during 4 h. 
Treated cells were heat inactivated at 65 °C for 1 h, washed 
three times with PBS, and adjusted to a final concentra-
tion of 2.5 × 1011 cfu/mL in PBS for the opsonophagocytic 
inhibition assay. For sodium meta-periodate treatment [15], 
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bacterial cells (≈109 cfu/mL) were incubated with sodium 
meta-periodate at a final concentration of 1 M for 24 h at 
room temperature in the dark. Sodium meta-periodate was 
neutralized with an excess of ethylene glycol at a final con-
centration of 2 M. Treated cells were washed three times 
with PBS and adjusted to a final concentration of 2.5 × 1011 
cfu/mL in PBS for opsonophagocytic inhibition assay.
Opsonophagocytic inhibition assay
For inhibition studies, either pre-treated bacterial cells 
or lipoteichoic acid was used as inhibitor. Pentaglobin 
(50 mg/mL) and Intratect (100 mg/mL) were diluted 1:25 
and incubated for 60 min at 4 °C with an equal volume of a 
solution containing 1.25 × 1011 cfu/mL of treated bacterial 
cells or 100, 20, 4 or 0.08 µg/mL of either lipoteichoic acid 
purified in our lab from E. faecalis 12030 or lipoteichoic 
acid from S. faecalis (E. faecalis) purchased from Sigma 
(St. Louis, Mo.). Subsequently, the respective mixtures 
of antibody and inhibitor was used in the opsonophagocytic 
assay (OPA) as described above. Inhibition assays were 
performed at serum dilutions yielding 50–80 % killing of 
the inoculum without the addition of the inhibitor. The per-
centage of inhibition of opsonophagocytic killing was com-
pared to controls without inhibitor.
Animal experiments
The protective efficacy of the monoclonal antibod-
ies was tested against CA-MRSA strain LAC in a mouse 
bacteremia model as described previously [11]. Five female 
BALB/c 6- to 8-week-old mice per group (Charles River 
Laboratories Germany GmbH) were infected by i.v. injec-
tion of CA-MRSA (5.0 × 107 cfu) via the tail vein. Anti-
bodies were given 48 and 24 h i.p. prior to bacterial chal-
lenge. Mice were killed 48 h after infection and organs 
(livers and kidneys) were aseptically removed, weighted 
and homogenized. Bacterial counts were enumerated after 
overnight incubation by plating serial dilutions on tryptic 
soy agar (TSA) plates. Statistical significance was assessed 
by Mann–Whitney test [12].
All animal experiments were performed in compliance 
with the German animal protection law (TierSchG). The 
animals were housed and handled in accordance with good 
animal practice as defined by FELASA and the national 
animal welfare body GV-SOLAS. The animal welfare 
committees of the University of Freiburg (Regierungsprae-
sidium Freiburg Az 35/9185.81/G-12/070) approved all 
animal experiments. The institutional review board of the 
University of Freiburg approved the study protocol.
Results
To assess the role of the IgM component with regard to 
opsonic killing, we compared Pentaglobin (IgG, IgM and 
IgA) with Intraglobin (only IgG). For the production of 
Intraglobin the same donor pool was used as for Pentaglobin.
Comparing the IgM-containing compound with the 
IgG compound against Gram-negative bacteria, significant 
Table 1  Bacterial strains, antigens and antisera used in this study
Bacteria Origin Reference/provider
E. faecalis 12030 Clinical isolate, Cleveland, OH, (gift from D. Shlaes) [14]
E. coli 4263 Outbreak isolate, strain collection University Hospital Freiburg
E. faecium 1162 Isolated from blood in the Netherlands, CC17 [27]
K. pneumonia 1436 Outbreak isolate, strain collection University Hospital Freiburg
K. pneumonia 1437 ESBL Outbreak isolate, strain collection University Hospital Freiburg
P. aeruginosa 2790 carbapenemase resistant Outbreak isolate, strain collection University Hospital Freiburg
S. aureus LAC CA-MRSA (USA300) [28]




 LTA Lipoteichoic acid from E. faecalis 12030 [9]
 LTA Lipoteichoic acid from Streptococcus (Enterococcus) faecalis Sigma
Antisera
 Intratect Contains only IgG (100 mg/mL) Biotest
 Intraglobin Contains only IgG (50 mg/mL), same donor pool as Pentaglobin  
(discontinued)
Biotest
 Pentaglobin 6 mg IgM, 6 mg IgA and 38 mg IgG (50 mg/mL), same donor pool  
as Intraglobin
Biotest
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killing was seen against ESBL-producing strain K. pneu-
moniae 1437 at a dilution of 1:10 (i.e., 68 % killing with 
Pentaglobin and 61 % with Intraglobin) (Fig. 1a). Higher 
killing could be observed in K. pneumoniae 1436, which at 
a dilution of 1:10 showed the best killing using Pentaglobin 
(83 %) and Intraglobin (95 %) (Fig. 1b). Clearly, less kill-
ing was observed in E. coli 4263 (47 %) and P. aeruginosa 
2790 (58,8 %) using Pentaglobin, and even less killing 
was seen with Intraglobin (28 % for E. coli 4263 and 23 % 
for P. aeruginosa 2790) (Fig. 1c, d). Overall, the IVIG 
preparation containing IgM shows higher killing rates in 
comparison to pure IVIG preparation Intraglobin against 
Gram-negative bacteria (Fig. 1).
To compare the IgM-containing compound with the 
pure IgG preparation against Gram-positive bacteria, kill-
ing rates of Pentaglobin and Intraglobin were also com-
pared against several nosocomial Gram-positive pathogens. 
Killing against vancomycin-resistant S. aureus was signif-
icantly higher with Pentaglobin (71 %) at a 1:10 dilution 
in comparison to Intraglobin (41 %) (Fig. 2a). However, 
Fig. 1  Opsonophagocytic kill-
ing of ESBL-producing strain 
K. pneumoniae 1437 (a), K. 
pneumoniae 1436 (b), E. coli 
4263 (c), and carbapenem-
resistant P. aeruginosa 2790 
(d). Opsonophagocytic assay 
was performed as described 
by Theilacker et al. using baby 
rabbit serum as complement 
source. IVIG preparations 
show significant opsonic killing 
against both K. pneumoniae 
strains. Higher killing against 
E. coli and P. aeruginosa was 
observed using Pentaglobin 
in comparison to Intraglobin. 
Killing is measured at dilutions 
of 1:10, 1:50, 1:100, 1:200 and 
1:500. Killing was dose depend-


















































































































































Fig. 2  Opsonophagocytic 
killing of VRSA-I strain (a), 
CA-MRSA LAC (b), E. faecalis 
12030 (c), and E. faecium 1162 
(d). Opsonophagocytic assay 
was performed as described 
by Theilacker et al. using baby 
rabbit serum as complement 
source. IVIG preparations 
show significant opsonic killing 
against all tested strains. Killing 
is measured at dilutions of 1:10, 
1:50, 1:100, 1:200 and 1:500. 
Killing was dose dependent 
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opsonic killing against CA-MRSA, E. faecalis as well as E. 
faecium was higher with Intraglobin (80–84 %) in compari-
son to Pentaglobin (73–74 %) (Fig. 2).
To assess the bacterial targets of the opsonic antibodies 
in the various immunoglobulin preparations, Pentaglobin 
and Intratect (the current commercially available IgG 
preparation), were used in an opsonophagocytic inhibi-
tion assay [16]. Since our previous results indicated that 
the glycerol phosphate backbone of LTA is the predomi-
nant target of protective antibodies against Gram-positive 
bacteria [12], we used an LTA preparation for absorptions, 
indicating that opsonic IgG antibodies against E. faeca-
lis in Intratect are directed against this epitope. Using the 
IgM-containing compound, only minimal absorption of 
killing was observed with purified LTA, indicating that 
the majority of opsonic antibodies in this preparation are 
not directed against this antigen (Fig. 3a). Opsonic killing 
activity of Intratect was inhibited with bacterial cells either 
treated with sodium meta-periodate or proteinase K, sug-
gesting that about 70 % of the antibodies of Intratect are 
directed against a polysaccharide target and 30 % against 
bacterial protein antigens. In contrast, opsonic antibod-
ies in Pentaglobin are only partially absorbed by bacterial 
cells treated with NaIO4 but quite efficiently by bacteria 
treated with proteinase K. This indicates that the major-
ity of opsonic antibodies in this preparation are directed 
against carbohydrate antigens, while a smaller number of 
opsonic antibodies are also directed against protein anti-
gens (Fig. 3b).
Using a previously described mouse sepsis model, 
we assessed the protective efficacy of the two antibody 
preparations in vivo (Fig. 4). Numbers of bacteria in liver 
and kidney of animals infected with MRSA strain LAC 
were significantly lower (1.0 × 104 cfu/g kidney and 
1.9 × 104 cfu/g liver) when animals received the IgG/IgM 
preparation Pentaglobin (300 mg/kg) compared to animals 
treated with Intratect (4.5 × 104 cfu/g kidney and 4.0 × 104 
cfu/g liver).
Discussion
The concept of using polyclonal human antibody prepara-
tions to treat and/or prevent bacterial infections has been 
pursued for a long time [17, 18]. However, results so far are 
rather disappointing. A large meta-analysis about the usage of 
IVIG in preterm neonates to prevent infectious complications 
found a rather low reduction of about 3 % in sepsis. However, 
this was not associated with a reduction in other clinically 
important outcomes, including mortality [19]. Similar obser-
vation has been made in other clinical settings [20].
The role of IgM is predominantly in the primary 
immune response of bacterial infections, and IgM eventu-
ally hypermutates and undergoes isotype switching [21]. 
Nevertheless, in many bacterial infections, the protective 
immune response is directed against carbohydrate antigens 
(such as capsular polysaccharides or glycoconjugates, such 
as teichoic acids) that are classic “T cell independent anti-
gens” and do not lead to isotype switching and memory B 
cell generation [22]. These antibodies seem to be critically 
important for the first-line defense against common bacte-
rial pathogens [8, 21].
Fig. 3  Opsonophagocytic inhibition assay comparing the target of 
Pentaglobin and Intratect. a Lipoteichoic acid is the target of opsonic 
antibodies against E. faecalis 12030 in Intratect, while Pentaglobin is 
only partially directed against LTA. b Opsonophagocytic inhibition 
assay after treating E. faecalis 12030 with proteinase K or NaIO4. 
Opsonic activity of Intratect is significantly inhibited when bacteria 
are treated with proteinase K (70 %) and inhibited by 30 % when 
bacteria are treated with NaIO4. Pentaglobin is only partially inhib-
ited with the cells treated with NaIO4 indicating that the majority 
of the antibodies are directed against polysaccharides and some are 
directed against protein antigens. The gray bar shows Killing against 
E. faecalis 12030 when sera raised against LTA from E. faecalis 
12030 were used and represent the positive control within this experi-
ment. Intratect and Pentaglobin were diluted 1:25 for the inhibition 
assay
174 F. S. Rossmann et al.
1 3
Only one commercially available antibody preparation, 
Pentaglobin, contains significant amounts (12 %) of IgM. 
In one study, this compound significantly reduced mortal-
ity, but had no overall effect on ICU length of stay [23]. 
On the other hand, Tugrul and colleagues [24] did not see 
such an effect and concluded that Pentaglobin did not have 
a positive effect on morbidity, incidence of septic shock, 
and mortality. Berlot et al. [20] pointed out that in general, 
the timing of the application of IVIG preparations is prob-
ably related to efficiency, similar to broad-spectrum anti-
biotics. The effect of IgM may also not be only directed 
against bacterial pathogens but may in addition lead to a 
modified anti-inflammatory response, such as up-regulation 
of IL-10 or down-regulation of IL-1β [25]. The selection of 
the study population and the overall study design seem to 
be of importance, because there are strong indications that 
certain subgroups, such as patients with streptococcal toxic 
shock syndrome caused by group A streptococcus, will 
benefit [26], while other more heterogeneous study popula-
tions may not exhibit positive results.
In our study, both antibody preparations showed broadly 
cross-reactive antibodies against the most notorious mul-
tiresistant pathogens, leading to significant opsonic kill-
ing of 50 % and higher at concentrations of 1.25 mg/mL 
against most of the strains tested. This amount corresponds 
to the human situation where similar amounts of immuno-
globulin should be obtained with the recommended doses 
of Pentaglobin or Intratect. Pentaglobin clearly showed 
better protection at lower dilutions (as low as 125 µg/mL), 
while Intraglobin did not show significant killing at these 
dilutions. Since the only difference between these prepara-
tions is the IgM (and IgA) content of Pentaglobin, this may 
indicate that the opsonic and protective antibodies are IgM.
At least against E. faecalis, the target of opsonic IgG anti-
bodies seems to be lipoteichoic acid, since absorption with 
purified LTA abrogated killing of this strain. For Pentaglobin, 
absorption with LTA did not result in significant inhibition of 
killing, although the majority of killing was abrogated after 
absorption with proteinase-treated bacterial cells. This indi-
cates that the targets of protective antibodies of both prepara-
tions differ to some extent, but are mainly directed against 
carbohydrate antigens (such as capsular polysaccharides). 
Killing in the opsonophagocytic assay is usually expressed in 
percent, although the effect is logarithmic. This explains the 
observation that inhibition with proteinase-K-treated bacteria 
treated with Na-periodate does not add up to 100 %. The ani-
mal model clearly shows protection against bacterial infec-
tions by both antibody preparations, although lower bacterial 
counts were observed with Pentaglobin, compared to Intra-
tect. Together, our data indicate that human immunoglobu-
lin preparations contain opsonic and protective antibodies 
against targets present on multiresistant Gram-positive and 
Gram-negative bacteria. Enrichment of these preparations 
with IgM increases the protective efficacy, probably due to 
antibodies directed against cell wall carbohydrates. Addi-
tional studies in well-defined clinical settings should confirm 
these findings.
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